News

Osaka and Tokyo (Japan), September 28, 2018 - Maruho Co., Ltd. ("Maruho", Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Galderma KK (Head Office: Tokyo, Japan, Representative Director: Tomonori Azuma) announce that from September 28, 2018, Maruho will succeed the manufacturing and marketing approval and marketing rights in Japan from Galderma KK for acne vulgaris treatment agent "Differin^® Gel 0.1%" (INN: adapalene, hereinafter referred to as "Differin").

Differin is a topical formulation of an acne vulgaris treatment developed by Galderma Pharma S.A. ("Galderma SA", Headquarters: Lausanne, Switzerland, CEO: Stuart Raetzman). Since its first marketing authorization in Europe in 1992, Differin has now been approved in 83 countries and areas around the world. In 2008 Galderma KK received manufacturing and marketing approval, and began marketing Differin in Japan.

Maruho and Galderma SA agreed to enter into a comprehensive set of agreements to form a strategic alliance focused on the development and commercialization of Galderma SA's prescription drugs for dermatology in Japan. From July 2016, Maruho has appropriately provided and collected medical information for Differin in Japan. From September 28, 2018, Maruho will appropriately provide and collect information as the manufacturer and distributor of Differin in Japan and will ensure a stable supply of this product.

As a pharmaceutical company specializing in dermatology, Maruho hopes to further contribute to patients suffering from acne vulgaris through the succession of marketing and manufacturing approval for Differin in Japan.

About Galderma
Galderma, Nestlé Skin Health's medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.
For more information, please visit https://www.galderma.com/

About Maruho
Maruho Co., Ltd. has its headquarters in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,459 employees (as of the end of September 2017), and net sales were approximately 79.95 billion yen in its fiscal year ending September 30, 2017. Pursuing its long-term corporate vision of "Excellence in Dermatology," Maruho is striving to improve the health and quality of life of people all over the world.
For more information, please visit https://www.maruho.co.jp/english/